Ola Landgren, MD, PhD from National Cancer Institute, Bethesda, MD talks about cardio-oncology in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.
Cardio-oncology in multiple myeloma
04 February 2016 |
Related To This Subject